EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Net Profit Margin since 2012
- Return on Equity (ROE) since 2012
- Return on Assets (ROA) since 2012
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
| 12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | ||||||
| Cost of capital2 | ||||||
| Invested capital3 | ||||||
| Economic profit4 | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
- Net Operating Profit After Taxes (NOPAT)
- The NOPAT showed a significant increase from 2020 to 2021, rising from 4,455 million USD to 12,362 million USD. This high level was somewhat maintained in 2022 with a slight decrease to 11,543 million USD. However, there was a sharp decline in 2023 to 3,292 million USD, followed by a moderate recovery to 4,563 million USD in 2024. Overall, the trend indicates volatility, with a peak in 2021 and 2022, and a notable drop thereafter.
- Cost of Capital
- The cost of capital exhibited a steady upward trend over the five-year period. Starting at 7.87% in 2020, it gradually increased each year to reach 9.55% by 2024. This rise suggests increasing capital costs or higher required returns by investors during this timespan.
- Invested Capital
- Invested capital decreased consistently from 2020 through 2023, falling from 103,725 million USD to 68,204 million USD. In 2024, there was a slight uptick to 69,263 million USD. This downward trend indicates a reduction in asset base or capital employed until 2023, with a marginal increase in the last year observed.
- Economic Profit
- Economic profit demonstrated considerable fluctuations across the period. In 2020, the company recorded a negative economic profit of -3,705 million USD. This swung positively in 2021 and 2022, with values of 4,031 million USD and 3,910 million USD respectively. The period then experienced a reversal to negative economic profit, with -3,193 million USD in 2023 and -2,054 million USD in 2024. This pattern reflects varying effectiveness in value creation relative to the company's cost of capital.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in restructuring reserve.
3 Addition of increase (decrease) in equity equivalents to net earnings attributable to AbbVie Inc..
4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
5 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
6 Addition of after taxes interest expense to net earnings attributable to AbbVie Inc..
7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
8 Elimination of after taxes investment income.
The financial data reveals significant fluctuations in key profitability metrics over the five-year period from 2020 to 2024. Net earnings attributable to the company show a marked increase between 2020 and 2021, more than doubling from 4,616 million USD to 11,542 million USD. This upward trend continued slightly into 2022, reaching 11,836 million USD. However, a sharp decline is observed in 2023, where net earnings drop to 4,863 million USD, followed by a further decrease in 2024 to 4,278 million USD.
Similarly, net operating profit after taxes (NOPAT) exhibits a strong growth trajectory in the initial years, rising from 4,455 million USD in 2020 to 12,362 million USD in 2021, before slightly decreasing to 11,543 million USD in 2022. In contrast to the early upward momentum, NOPAT experiences a significant fall in 2023 to 3,292 million USD, although it recovers somewhat in 2024 to 4,563 million USD.
- Net Earnings Attributable to the Company
- Demonstrated substantial growth in the first two years, peaking in 2022.
- Experienced a pronounced decline in the subsequent years, reaching the lowest point in 2024 within the presented timeframe.
- Net Operating Profit After Taxes (NOPAT)
- Followed a similar pattern to net earnings, with rapid growth through 2021, slight reduction in 2022.
- Showed a sharp decline beginning in 2023, with modest recovery in 2024 albeit remaining well below earlier peak levels.
Overall, the data points toward a period of strong profitability gains up to 2022, followed by notable erosion in both net earnings and NOPAT over the last two years. The decline in profitability metrics during 2023 and 2024 suggests the presence of operational challenges or market conditions adversely impacting financial performance. The partial resurgence of NOPAT in 2024 hints at potential stabilization or early signs of financial recovery.
Cash Operating Taxes
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Income Tax Expense (Benefit) Trend
- The income tax expense exhibited significant volatility over the analyzed period. It began with a notable benefit of -$1,224 million at the end of 2020, indicating a tax gain or credit that reduced tax burden during that year. This reversed sharply in 2021 to a tax expense of $1,440 million, then further increased to $1,632 million in 2022. In 2023, it slightly decreased but remained high at $1,377 million. However, in 2024, the income tax expense again turned negative, showing a benefit of -$570 million. This pattern suggests fluctuating tax positions or adjustments possibly due to changes in tax regulations, earnings variations, or deferred tax accounting impacts.
- Cash Operating Taxes Trend
- The cash operating taxes consistently increased from 2020 through 2023, indicating increasing cash payments for taxes despite fluctuations in reported income tax expense. In 2020, cash taxes were $1,585 million, which rose significantly each year to reach $4,625 million in 2023. However, in 2024, there was a notable decline in cash operating taxes to $1,339 million, which is substantially lower than the prior years. This decline could suggest a one-time tax payment adjustment, changes in taxable income, tax credits utilization, or other operational tax strategies impacting cash outflows.
- General Observations
- While reported income tax expenses fluctuated between benefits and expenses, cash taxes paid showed a general increasing trend until a sharp drop in 2024. The divergence between income tax expense and cash operating taxes through the years implies differences between accounting recognition of tax expenses and actual tax payments, which is common in companies with complex tax structures. The decline in both income tax expense and cash operating taxes in 2024 may indicate significant tax planning outcomes or shifts in profitability affecting tax liabilities.
Invested Capital
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of restructuring reserve.
4 Addition of equity equivalents to stockholders’ equity.
5 Removal of accumulated other comprehensive income.
6 Subtraction of construction in progress.
7 Subtraction of available-for-sale investment securities.
The financial data over the provided periods reveal several significant trends related to debt, equity, and capital structure.
- Total reported debt & leases
- The total reported debt and leases exhibit a decreasing trend from 87,063 million USD at the end of 2020 to 60,286 million USD by the end of 2023, reflecting a substantial reduction in leverage over the first four years. However, in 2024, there is a noticeable increase to 68,019 million USD, indicating a reversal of the prior downward trend in debt levels.
- Stockholders’ equity
- Stockholders' equity initially increases from 13,076 million USD in 2020 to a peak of 17,254 million USD in 2022. Subsequently, it declines sharply to 10,360 million USD in 2023 and continues to deteriorate significantly in 2024, dropping to 3,325 million USD. This steep decrease in equity over the last two years suggests increased challenges with retained earnings or potential capital losses.
- Invested capital
- Invested capital shows a consistent downward trajectory, reducing from 103,725 million USD in 2020 to 68,204 million USD in 2023. Unlike other trends, invested capital appears to stabilize in 2024 with a slight increase to 69,263 million USD, signaling a possible floor or minor recovery in invested assets or operational capital use.
Overall, the data suggest a focused effort on debt reduction from 2020 to 2023 accompanied by increasing equity till 2022. However, the last two years highlight financial stress with declining equity and rising debt, raising concerns about the company’s capital structure stability and financial leverage. The decline and subsequent stabilization in invested capital corroborate a contraction phase followed by an attempt to maintain or increment operational investment.
Cost of Capital
AbbVie Inc., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2020-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| Economic spread ratio3 | ||||||
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
- Economic Profit Trends
- The economic profit exhibited significant fluctuations over the analyzed periods. Initially, there was a substantial economic loss of -3,705 million US dollars at the end of 2020. This shifted positively to 4,031 million US dollars in 2021 and slightly decreased but remained strong at 3,910 million in 2022. However, the trend reversed sharply in the subsequent years, with economic profit declining to -3,193 million in 2023 and further reducing to -2,054 million in 2024. This pattern indicates volatility in the company’s ability to generate profits above its cost of capital.
- Invested Capital Trends
- Invested capital showed a consistent downward trend from 2020 through 2023, decreasing from 103,725 million US dollars to 68,204 million US dollars. In 2024, this trend slightly reversed with a marginal increase to 69,263 million. The reduction in invested capital over the majority of the period suggests divestitures or a reduction in asset base, possibly impacting the economic profit outcomes.
- Economic Spread Ratio Insights
- The economic spread ratio followed a similar fluctuating pattern as economic profit. Starting with a negative ratio of -3.57% in 2020, it improved significantly to 4.2% in 2021 and increased further to 4.76% in 2022, indicating periods of efficient capital use and value creation. Nevertheless, the ratio became negative again in 2023 (-4.68%) and improved slightly but remained negative in 2024 (-2.97%). This oscillation reinforces the observation of inconsistent economic value generation during the period.
- Summary
- The data reveals cyclical performance with two years of positive economic profit and economic spread ratios enclosed by periods of negative performance. The declining invested capital over much of the timeline could be correlated to the fluctuations in profitability and capital efficiency. The company experienced difficulty maintaining consistent economic profits and returns above cost of capital in the latest years, suggesting challenges in sustaining value creation.
Economic Profit Margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | ||||||
| Net revenues | ||||||
| Performance Ratio | ||||||
| Economic profit margin2 | ||||||
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Net revenues
= 100 × ÷ =
3 Click competitor name to see calculations.
- Net Revenues
- Net revenues demonstrated an overall upward trend over the five-year period. Starting at $45,804 million, revenues increased significantly to $56,197 million in the following year. This positive momentum continued, reaching a peak of $58,054 million by the end of 2022. Despite a slight decline to $54,318 million in 2023, revenues recovered to $56,334 million in 2024, indicating resilience and a generally stable revenue base.
- Economic Profit
- The economic profit figures showed considerable volatility during the period. The company experienced a substantial economic loss of $3,705 million in 2020. The following two years saw a strong reversal, with economic profits turning positive and peaking at $4,031 million in 2021, slightly declining to $3,910 million in 2022. However, in 2023 and 2024, economic profit returned to negative territory, registering losses of $3,193 million and $2,054 million respectively. This fluctuation suggests challenges in sustaining profitability beyond 2022.
- Economic Profit Margin
- Similar to economic profit, the economic profit margin exhibited significant swings. Losses measured by margins were at -8.09% in 2020, followed by improvements to positive margins of 7.17% in 2021 and 6.74% in 2022. These gains were reversed afterward, with margins falling to negative values at -5.88% in 2023 and -3.65% in 2024. The margins' pattern aligns with economic profit, signaling variability in profitability efficiency despite relatively stable revenue levels in later years.
- Overall Analysis
- While net revenues showed steady growth with minor fluctuations, economic profit and economic profit margin trends highlight periods of both robust profitability and notable losses. The significant gains in 2021 and 2022 were not maintained, leading to renewed economic losses in subsequent years. This disparity suggests that increased revenues did not consistently translate into sustainable economic profits, implying potential issues with cost management, investments, or other financial factors affecting economic returns during the latter years.